Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 62199.38 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 1215.74 Crore, up 30.03 % from last quarter Total Income of Rs 934.96 Crore and up 32.68 % from last year same quarter Total Income of Rs 916.29 Crore. Company reported net profit after tax of Rs 350.65 Crore in latest quarter.
Investment Rationale
The brokerage remains positive on GLAND due to its: a) superior ramp-up in existing products, b) healthy build-up in the complex product pipeline, c) ongoing investment in the vaccine/Biological space, and d) enough scope for inorganic growth as well. It reiterates Buy rating.
Promoter/FII Holdings
Promoters held 58.3 per cent stake in the company as of March 31, 2021, while FIIs held 11.9 per cent, DIIs 11.3 per cent and public and others 18.6 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
